美国联邦贸易委员会（FTC）当地时间1月14日发布报告称，美国多家药物福利管理公司通过对治疗癌症和艾滋病的药物收取“巨额加价”，产生超73亿美元收入。 FTC点名了CVS健康旗下Caremark、 信诺 旗下Express Scripts和联合健康集团旗下的Optum，它们管理着美国约80%处方药。

The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

Major pharmacy-benefit managers generated $7.3 billion in markups on specialty drugs from pharmacies they are affiliated with ...

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 ...

The three biggest pharmacy benefit managers made more than $7.3 billion over five years marking up the prices of specialty ...

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...

For the second time in less than a year, the FTC has released a highly critical report of pharmacy benefit managers, or PBMs.

The FDC released a second highly critical report of PBMs, which may provide further impetus for legislative action to curb ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in revenue from marking up the prices of dozens of specialty generic drugs ...

FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...

Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...